logo
The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

Yahoo08-07-2025
Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when its mRNA-based COVID-19 vaccine was one of the first to be granted emergency-use authorization and distributed globally. This opportunity also validated Moderna's mRNA platform's effectiveness and scalability, boosting the company's stock price by more than 1,200% between 2020 and 2022.
Another such clinical-stage contender generating growing excitement is Intellia Therapeutics (NTLA), a CRISPR/Cas9-based gene-editing company. Intellia aims to provide one-time, curative treatments for serious genetic diseases. Intellia's stock has fallen 1.9% year-to-date, while the broader market, as tracked by the S&P 500 Index ($SPX), has risen 6%.
This Analyst Just Raised His Broadcom Stock Price Target by 70%. Should You Buy AVGO Now?
Why Alibaba Stock Looks Like a Screaming Buy After Falling 27% From Its 2025 Highs
2 ETFs Offering Juicy Dividend Yields of 20% or Higher
Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.
Let's dig deeper to see if this could be the next transformative biotech story that reshapes medicine — and markets — in the same way Moderna did.
Intellia employs a dual-platform strategy, focusing on both in vivo (inside the patient's body) and ex vivo (outside the patient's body) approaches to treating conditions such as transthyretin amyloidosis (ATTR) and hereditary angioedema (HAE). Intellia's lead in vivo therapies include NTLA-2001 (Nexiguran ziclumeran or nex-z), a treatment for ATTR amyloidosis that is in the Phase 3 MAGNITUDE trial. Nex Z was also granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA), indicating its potential for accelerated development.
NTLA-2002, a treatment for hereditary angioedema (HAE), is now in late-stage clinical trials. In the first quarter of 2025, Intellia administered the first dose in the HAELO trial. This event marks a critical inflection point, bringing Intellia closer to regulatory filings and possible approval. However, the company recently halted its NTLA-3001 lung disease candidate, as well as several other research programs. It also reduced its workforce by about 27%, causing a short-term disruption. The goal of this strategic reorganization is to increase focus on late-stage assets while conserving capital.
While Intellia does not yet generate product revenue, it did generate $16.6 million in collaboration revenue during the first quarter. As of Q1 end, the company held $707.1 million in cash and executed a 27% workforce reduction, ensuring a runway until the first half of 2027.
Intellia's first-mover advantage in in vivo gene editing could propel it to great success if its candidates are approved. The company has also collaborated with heavyweights like Regeneron (REGN), gaining expertise, resources, and a broader clinical reach.
However, as a clinical-stage biotech company, the company faces the risk of clinical trials failing or delays in regulatory approvals because gene editing is a high-stakes game. Furthermore, increased cash burn may necessitate dilution. Long-term growth investors who believe in CRISPR's transformative potential may view NTLA stock as an enticing but high-risk investment opportunity.
Overall, Wall Street has assigned Intellia stock a 'Moderate Buy' rating. Of the 27 analysts covering NTLA stock, 19 have a 'Strong Buy' recommendation, one suggests a 'Moderate Buy,' six say it is a 'Hold,' and one suggests a 'Strong Sell.' The average price target of $38.04 implies the stock has upside potential of 245% over current levels. Plus, the Street-high price estimate of $106 suggests the stock can rally over 860% over the next 12 months.
While the upside appears out of reach, Moderna stock is a prime example of how a single successful product can propel a biotech stock toward the skies. Intellia, like Moderna, focuses on diseases with high clinical need and, if successful, has the potential to transform medicine.
On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Bloomberg Daybreak Asia: One Week Left For Trade Talks
Bloomberg Daybreak Asia: One Week Left For Trade Talks

Bloomberg

time23 minutes ago

  • Bloomberg

Bloomberg Daybreak Asia: One Week Left For Trade Talks

The US and Japan this week reached what President Donald Trump called the largest trade deal in history after Tokyo pledged to set up a $550 billion fund for investment into the US, details of which remain obscure. The lack of clarity about how the fund will work adds to questions about the viability of the agreement, which imposes 15% tariffs on Japanese cars and other goods. While the start date and other basic elements are still unknown, Treasury Secretary Scott Bessent warned this week that the US would monitor implementation and bump the rate up to 25% if Trump isn't satisfied. In his latest column, Bloomberg Opinion's Gearoid Reidy writes that after three months, Prime Minister Shigeru Ishiba finally has his trade deal. Gearoid joins us to explain why it may be Ishiba's final act. Plus - the S&P 500 inched to a new record Thursday - its 10th in 19 days - driven by tech gains that papered over a broader weakness as most stocks in the benchmark dropped. The S&P 500 has surged 28% from its April lows as investors grew optimistic that President Donald Trump's tariff war won't hurt the economy and corporate earnings as initially feared. Meantime, South Korea's trade ministry said Friday that Industry Minister Kim Jung-kwan and US Commerce Secretary Howard Lutnick reaffirmed their will to reach a mutually beneficial trade agreement before August 1st deadline. For more on the economic impact of ongoing negotiations, we heard from Janet Henry, Global Chief Economist at HSBC. She speaks with Bloomberg's Shery Ahn and Haidi Stroud-Watts on The Asia Trade.

Prospects of Higher Indian Sugar Exports Weigh on Prices
Prospects of Higher Indian Sugar Exports Weigh on Prices

Yahoo

time35 minutes ago

  • Yahoo

Prospects of Higher Indian Sugar Exports Weigh on Prices

October NY world sugar #11 (SBV25) on Wednesday closed down -0.04 (-0.25%), and October London ICE white sugar #5 (SWV25) closed down -0.80 (-0.17%). Sugar prices extended this week's slide on Wednesday, with NY sugar posting a 2.5-week low and London sugar posting a 2-week low. Sugar prices were under pressure on Wednesday due to speculation that India may boost its sugar exports after a Bloomberg report stated that the country may permit local sugar mills to export sugar in the next season, which starts in October, as abundant monsoon rains may produce a bumper sugar crop. India's Meteorological Department reported Monday that cumulative monsoon rain in India is 6% above normal as of July 21. More News from Barchart Coffee Prices Rise on Frost Threats in Brazil Frost Threats in Brazil Push Coffee Prices Sharply Higher Signs of Weak Chocolate Demand Undercut Cocoa Prices Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. The outlook for higher sugar production in Brazil is also weighing on sugar prices. Datagro said Monday that dry weather in Brazil has encouraged the country's sugar mills to increase their cane crushing, diverting more of the cane crush toward more profitable sugar production rather than ethanol. According to Covrig, Brazil's sugar mills are expected to crush 54% of the available cane in the first half of this month, likely adding 3.2 MMT of sugar into the market. The outlook for higher sugar production in India, the world's second-largest producer, is bearish for prices. On June 2, India's National Federation of Cooperative Sugar Factories projected that India's 2025/26 sugar production would climb +19% y/y to 35 MMT, citing larger planted cane acreage. That would follow a -17.5% y/y decline in India's sugar production in 2024/25 to a 5-year low of 26.2 MMT, according to the Indian Sugar Mills Association (ISMA). Also, the ISMA reported on July 7 that India's sugar production during Oct 1-May 15 fell -17% y/y to 25.74 MMT. Sugar prices have retreated over the past three months, with NY sugar falling to a 4.25-year low earlier this month and London sugar sliding to a nearly 4-year low, driven by expectations of a sugar surplus in the 2025/26 season. On June 30, commodities trader Czarnikow projected a 7.5 MMT global sugar surplus for the 2025/26 season, the largest surplus in 8 years. On May 22, the USDA, in its biannual report, projected that global 2025/26 sugar production would increase by +4.7% y/y to a record 189.318 MMT, with global sugar ending stocks at 41.188 MMT, up 7.5% y/y. Last Friday, NY sugar posted a 7-week high and London sugar posted a 2-month high, driven by signs of stronger global sugar demand. China's June sugar imports soared by 1,435% to 420,000 MT. Also, President Trump last Wednesday said Coca-Cola agreed to use cane sugar in Coke beverages sold in the US instead of high-fructose corn syrup, which could boost US sugar consumption by +4.4% to 11.5 MMT from 11 MMT currently, according to Bloomberg Intelligence. Sugar prices also have support from reduced sugar production in Brazil. Unica reported last Monday that the cumulative 2025/26 Brazil Center-South sugar output through June fell by -14.3% y/y to 12.249 MMT. Last month, Conab, Brazil's government crop forecasting agency, said 2024/25 Brazil sugar production fell by -3.4% y/y to 44.118 MMT, citing lower sugarcane yields due to drought and excessive heat. The outlook for higher sugar production in Thailand is bearish for sugar prices. On May 2, Thailand's Office of the Cane and Sugar Board reported that Thailand's 2024/25 sugar production rose +14% y/y to 10.00 MMT. Thailand is the world's third-largest sugar producer and the second-largest exporter of sugar. The International Sugar Organization (ISO) raised its 2024/25 global sugar deficit forecast to a 9-year high of -5.47 MMT on May 15, up from a February forecast of -4.88 MMT. This indicates a tightening market following the 2023/24 global sugar surplus of 1.31 MMT. ISO also cut its 2024/25 global sugar production forecast to 174.8 MMT from a February forecast of 175.5 MMT. The USDA, in its bi-annual report released May 22, projected that global 2025/26 sugar production would climb +4.7% y/y to a record 189.318 MMT and that global 2025/26 human sugar consumption would increase +1.4% y/y to a record 177.921 MMT. The USDA also forecasted that 2025/26 global sugar ending stocks would climb +7.5% y/y to 41.188 MMT. The USDA's Foreign Agricultural Service (FAS) predicted that Brazil's 2025/26 sugar production would rise +2.3% y/y to a record 44.7 MMT FAS predicted that India's 2025/26 sugar production would rise +25% y/y to 35.3 MMT due to favorable monsoon rains and increased sugar acreage. FAS predicted that Thailand's 2025/26 sugar production will climb +2% y/y to 10.3 MMT. On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Why ServiceNow Stock Surged Today
Why ServiceNow Stock Surged Today

Yahoo

timean hour ago

  • Yahoo

Why ServiceNow Stock Surged Today

Key Points ServiceNow stock rose today following the company's second-quarter earnings report. The enterprise software specialist beat Wall Street's sales and earnings targets for Q2, and it raised its subscription revenue forecast for this year. ServiceNow is seeing strong AI-related tailwinds and looks poised to continue benefiting from digital transformation trends. 10 stocks we like better than ServiceNow › ServiceNow (NYSE: NOW) stock posted gains in Thursday's trading following the company's latest quarterly report. The software specialist's share price gained 4.2% in the session and had been up as much as 9.9% early in the day's trading. ServiceNow published its second-quarter results after the market closed yesterday, and the numbers came in better than Wall Street had anticipated. The company's report showed continued artificial intelligence (AI) tailwinds, and management raised full-year performance targets for the business. ServiceNow stock jumps on strong Q2 numbers ServiceNow recorded non-GAAP (adjusted) earnings per share of $4.09 on sales of $3.22 billion in the second quarter, beating the average analyst estimate's call for per-share earnings of $3.57 per share on sales of $3.12 billion in the period. Revenue was up roughly 22% year over year, and the business closed out the quarter with remaining performance obligations of $23.9 billion -- representing growth of 25.5% on a currency-adjusted basis. What's next for ServiceNow? ServiceNow is seeing strong AI-related demand for its enterprise software suite, and the company has raised its performance outlook for the year on the heels of strong results in the second quarter. Management is now guiding for subscription revenue to come in between $12.77 billion and $12.79 billion. At the midpoint, the new guidance is up by $125 million compared to its previous forecast. As a leading enterprise software provider, ServiceNow looks poised to continue benefiting from AI and digital transformation trends. While gains for the company's valuation could open the door for downside volatility in the near term, the company looks poised to deliver wins for shareholders over the long haul. Should you invest $1,000 in ServiceNow right now? Before you buy stock in ServiceNow, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and ServiceNow wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $634,627!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,046,799!* Now, it's worth noting Stock Advisor's total average return is 1,037% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends ServiceNow. The Motley Fool has a disclosure policy. Why ServiceNow Stock Surged Today was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store